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Abstract
Background
The correlation of low serum albumin with mortality in patients with chronic kidney disease
(CKD) is partly linked to its association with systemic inflammation. However, it is not clear
to what extent albumin’s correlation with mortality depends on concomitant systemic inflam-
mation. Here we addressed this question in patients with CKD stage 5.
Methods
Serum albumin (S-Alb), systemic inflammation (high-sensitive C-reactive protein, hsCRP),
cardiovascular disease (CVD) and nutritional status (subjective global assessment, SGA)
were assessed at baseline in 822 patients: 523 incident dialysis patients, 212 prevalent
hemodialysis (HD) and 87 prevalent peritoneal dialysis (PD) patients. Patients were divided
into four groups according to hsCRP and S-Alb in each cohort: Group 1 –normal S-Alb and
normal hsCRP (reference); Group 2 –low S-Alb and normal hsCRP; Group 3—normal S-Alb
and high hsCRP; Group 4—low S-Alb and high hsCRP. Survival over 60 months was
analyzed.
Results
In Cox analysis, Group 4 had an increased mortality risk (adjusted Hazard ratio (95% confi-
dence interval): 1.62 (1.06–2.47); p = 0.02) whereas the augmented mortality risks for
Groups 2 and 3 in univariate analyses were not significant after adjustments for age, gender,
blood pressure, diabetes mellitus, smoking, SGA, renal function and renal replacement
technique.
Conclusions
Whereas mortality risk was increased in CKD stage 5 patients with low S-Alb and high CRP,
it was not increased in patients with low S-Alb and normal CRP. Our observation suggests
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Introduction
Hypoalbuminemia is a frequent feature of chronic kidney disease (CKD) [1, 2] and associates
with poor clinical outcome [3, 4]. Serum albumin (S-Alb) was former considered a biomarker
of visceral protein and immunocompetence status, fundamental to nutritional assessment [5].
However, recent studies show that low S-Alb rather reflects a state of persistent inflammation
[6–8] and has limited value as a marker of nutritional status [9, 10]. Indeed, in the Minnesota
study [11], an experiment of human semi-starvation in healthy individuals, S-Alb did not
reflect nutritional changes nor body weight variation. A similar scenario was reported in
patients with anorexia nervosa [12]. Despite the multiple essential functions of albumin (main-
taining colloid osmotic pressure, transporting nutrients, hormones and drugs, serving as a free
radical scavenger and having antithrombotic properties [13]) patients with the rare congenital
disorder analbuminemia have mild or even absent symptoms [14].
Persistent inflammation, usually assessed by C-reactive protein (CRP) levels, is a character-
istic feature in CKD, caused by multiple factors of the toxic uremic milieu and the dialysis
technique itself [13, 15–17]. Inflammation contributes to decreased S-Alb levels [18] and plays
a central role in the Malnutrition, Inflammation and Atherosclerosis syndrome (MIA) [15,
19], which associates with poor cardiovascular outcomes [20]. There is no consensus regarding
the appropriate cut-off concentration for CRP in CKD, making it problematic to ascertain and
understand the magnitude, variability and consequences of uremic inflammation [16, 21, 22].
Based on the inflammation-catalyst hypothesis [23]; i.e., persistent inflammation exacer-
bates the effect of other risk factors in the uremic milieu, we hypothesized that inflammation
would have a catalytic effect on hypoalbuminemia as a risk predictor. Thus, the effect of sus-
tained inflammation on S-Alb levels, through inhibition of its synthesis and induction of its
catabolism [24], would be mainly responsible for the documented association between mortal-
ity and hypoalbuminemia [7, 13]. Albumin has a longer half-life and lower variability than tra-
ditional inflammatory markers, such as CRP [22], and may better reflect sustained
inflammation. Therefore, the operational hypothesis of the current study is that S-Alb and
CRP–two biochemical parameters easily accessible in clinical daily practice–should be used
together for an improved risk assessment. We tested this hypothesis in incident and prevalent
dialysis patients.
Materials and methods
Patients and study design
This prospective observational study was conducted in 822 patients, comprising data from
four independent cohorts described in detail previously [25–28]. Incident dialysis patients
were recruited among consecutive patients initiating dialysis at the Department of Renal Med-
icine, Karolinska University Hospital, from June 1994 until November, 2014 as part of the
ongoing MIA (Malnutrition, Inflammation Atherosclerosis) study; see [15, 19, 26] for further
details regarding all aspects of study design. 51 prevalent PD patients were recruited from May
2008 to January 2011 in the MIMICK 2 (Mapping of Inflammation Markers in Chronic Kid-
ney Disease 2) study among all prevalent PD patients treated in Stockholm; see [27] for further
details regarding all aspects of study design. 174 prevalent HD patients were recruited from
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November 2003 until September 2004 in the MIMICK 1 (Mapping of Inflammation Markers
in Chronic Kidney Disease 1) study among all prevalent HD patients treated in Stockholm; see
[22] for further details regarding all aspects of study design. 36 prevalent PD patients and 38
prevalent HD patients were recruited from May 2009 to June, 2016 in an ongoing study of vas-
cular changes in ESRD patients undergoing living donor renal transplantation (LD-Rtx study);
see [28] for further details. They were there upon redistributed according to the renal replace-
ment status in 523 incident dialysis patients, 212 prevalent hemodialysis (HD) patients and 87
prevalent peritoneal dialysis (PD) patients. Patients´ characteristics at baseline in these three
cohorts are displayed in S1 Table.
The patients were divided in normal or low S-Alb, using the cutoff of 35 g/L, and in normal
or high high-sensitive CRP (hsCRP), using the cutoff of 3 mg/L, and consequently divided into
four groups: Group 1 (n = 200)–normal S-Alb and normal hsCRP; Group 2 (n = 160)—low
S-Alb and normal hsCRP; Group 3 (n = 172)–normal S-Alb and high hsCRP; Group 4
(n = 290)—low S-Alb and high hsCRP. Typical cardiovascular risk factors (i.e., age, gender,
hypertension, diabetes mellitus, dyslipidemia, smoking) and atypical, or CKD-related cardio-
vascular risk factors, i.e., anemia, bone-mineral disorder, inflammation, protein-energy wast-
ing (PEW; subjective global assessment) and oxidative stress, where compared among the four
groups (Table 1). Survival was determined after a follow-up period of 60 months. There were
no patients lost to follow-up. The Ethics Committee of the Karolinska Institute, Stockholm,
Sweden, approved the study protocol. Informed written consent was obtained from each
patient.
Clinical, anthropometric and nutritional evaluation
Cardiovascular disease (CVD) was defined by medical history or clinical findings of cardiac,
cerebrovascular or peripheral arterial disease. Smoking habits were recorded as current and
former smokers and non-smokers. Anthropometric measurements were obtained at the base-
line, after the dialysis session in case of prevalent HD patients. Body mass index (BMI) was cal-
culated. Handgrip strength (HGS) was measured in both hands using a Harpenden Handgrip
Dynamometer (Yamar, Jackson, MI, USA). The dominant hand measurement was used in our
analysis due to the regular presence of arteriovenous fistulas in the non-dominant arm. Values
for HGS were expressed as percentage of healthy subjects, adjusted for gender.
Nutritional status was evaluated using the 6 components of the subjective global assessment
(SGA) questionnaire: patient’s history of weight loss, anorexia and vomiting, and physician’s
grading of muscle wasting, presence of oedema and loss of subcutaneous fat [29]. Poor nutri-
tional status was defined as a SGA>1. Arterial systolic and diastolic blood pressure was mea-
sured three times in the morning after a 15-minute resting period.
Biochemical analysis
Venous blood samples were collected at baseline, before the dialysis session in hemodialysis
patients. The plasma was separated and samples were kept frozen at –70˚ C if not analysed
immediately. S-Alb concentration was measured with bromocresol purple method; hsCRP con-
centration by nephelometry; and concentrations of hemoglobin, creatinine, ferritin, cholesterol,
triglycerides, parathyroid (PTH), calcium and phosphate were determined by routine methods
at the Department of Laboratory Medicine, Karolinska University Hospital. Interleukin-6 (IL-
6) and plasma tumor necrosis factor (TNF) were analyzed by enzyme-labeled chemiluminescent
assay (Immulite, DPC, Los Angeles, CA); serum 8-OHdG by commercial competitive enzyme-
linked immunosorbent assay (ELISA) kit (Japan Institute for the Control of Aging, Shizuoka,
Japan); and vascular cellular adhesion molecule 1 (VCAM-1) by commercial ELISA kits.
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Table 1. Demographic, clinical and laboratory characteristics of 822 CKD stage 5 patients divided into four groups defined according to levels of
serum albumin and hsCRP.
Characteristics Group 1
Normal albumin
Normal hsCRP
(n = 200)
Group 2
Low albumin
Normal hsCRP
(n = 160)
Group 3
Normal albumin
High hsCRP
(n = 172)
Group 4
Low albumin
High hsCRP
(n = 290)
p value
CKD5/HD/PD (%) 65/24/11 63/19/19 62/34/5 64/26/9 0.001
Residual renal function (ml/min/1.73 m2) 5.3 (0.0–9.4) 4.9 (0.0–10.1) 5.0 (0.0–9.5) 5.2 (0.0–8.9) 0.92
Urinary albumin excretion (mg/24h) a 16023 (145–4008) 2228 (225–7945) 1262 (86–4443) 2380 (349–6220) <0.001
Traditional cardiovascular risk factors
Age (years) 47 (26–70) 55 (32–74) 59 (37–76) 61 (39–75) <0.001
Gender (male %) 61 50 67 64 0.01
Cardiovascular disease (%) 24 29 48 48 <0.001
Diabetes mellitus (%) 12 33 24 34 <0.001
Smoking (%) b 39 43 60 62 <0.001
Systolic BP (mmHg) c 140 (120–172) 147 (120–180) 143 (112–171) 145 (110–180) 0.07
Diastolic BP (mmHg) c 85 (70–101) 87 (70–103) 82 (65–97) 84 (65–103) 0.14
BMI (kg/m2) 23.5 (19.1–29.0) 24.6 (20.3–30.2) 24.7 (20.4–30.6) 24.0 (18.9–30.5) 0.003
Cholesterol (mmol/L) d 4.6 (3.3–6.5) 4.8 (3.3–6.9) 4.6 (3.4–6.4) 4.6 (3.0–7.0) 0.63
Triglycerides (mmol/L) e 1.5 (0.8–2.8) 1.5 (0.7–2.8) 1.7 (0.8–3.5) 1.7 (0.9–3.2) 0.004
Uremia related cardiovascular risk factors
Hemoglobin (g/L) 114 (95–131) 109 (93–129) 110 (92–128) 106 (86–127) <0.001
Ferritin (ng/ml) f 288 (93–753) 269 (58–561) 335 (99–798) 330 (104–897) 0.007
Serum albumin (g/L) 38 (35–42) 32 (26–33) 37 (35–41) 30 (24–34) <0.001
SGA score >1 (%) 27 28 37 48 <0.001
Handgrip strength (% of control) 92 (56–121) 83 (58–122) 77 (48–114) 67 (41–103) <0.001
PTH (ng/L) g 251 (48–631) 220 (70–515) 207 (56–638) 248 (56–610) 0.26
Calcium (mmol/L) h 2.42 (2.13–2.71) 2.31 (2.05–2.69) 2.51 (2.18–2.75) 2.42 (2.05–2.75) <0.001
Phosphate (mmol/L) i 1.8 (1.2–2.6) 1.8 (1.2–2.5) 1.8 (1.3–2.6) 1.9 (1.2–2.6) 0.48
hsCRP (mg/L) 1.1 (0.3–2.5) 1.2 (0.2–2.6) 7.9 (3.8–28.0) 14.0 (4.2–58.3) <0.001
IL-6 (pg/ml) j 2.8 (0.5–8.4) 3.8 (0.9–9.9) 6.7 (2.1–15.8) 9.6 (4.2–25.4) <0.001
TNF (pg/ml) k 11.6 (7.5–18.2) 10.9 (6.6–18.0) 12.9 (7.8–19.4) 14.4 (8.5–24.7) <0.001
VCAM-1 (ng/ml) l 1205 (810–1895) 1301 (873–1700) 1398 (824–2027) 1574 (1043–2795) <0.001
8-OHdG (ng/ml) m 0.63 (0.15–1.56) 0.54 (0.14–1.39) 0.73 (0.31–1.72) 0.85 (0.42–1.88) <0.001
Abbreviations: BP, blood pressure; BMI, body mass index; SGA, subjective global assessment of nutritional status; PTH, parathyroid hormone; hsCRP,
high-sensitivity C-reactive protein; IL-6, interleukin-6; TNF, tumor necrosis factor; VCAM-1, vascular cellular adhesion molecule-1; 8-OHdG, 8-hydroxy-2’-
deoxyguanosine. Low albumin was defined as S-Alb levels <35g/L, High hsCRP was defined as hsCRP levels3mg/L, Normal albumin was defined as
S-Alb levels35g/L and Normal hsCRP levels was defined as hsCRP levels <3 mg/L. Values presented as median (range 10th to 90th percentiles).
a n = 300
b n = 678
c n = 703
d n = 817
e n = 815
f n = 687
g n = 725
h n = 790
i n = 785
j n = 789
k n = 754
l n = 480
m n = 528.
https://doi.org/10.1371/journal.pone.0190410.t001
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Statistical analysis
Continuous variables were expressed as median with range 10th to 90th percentile and Chi-
square was used for nominal variables. Nonparametric ANOVA were used for three or more
groups: Kruskal-Wallis test for continuous variables, followed by Dunn’s test. Spearman rank
test was used for correlation between continuous and ordinal variables. Statistical significance
was set at the level of p<0.05. Imputation of missing values was performed using the function
MI. The datasets were limited to ten imputations to avoid overestimation due to Monte Carlo
variability. Survival analysis was performed using Kaplan-Meier survival curves and Cox pro-
portional hazard models. Hazard ratios with 95% confidence interval for mortality were
adjusted for age, gender, CVD, diabetes mellitus, smoking, residual renal function and treat-
ment modality. Cox model assumptions were tested using Schoenfeld residuals plot for pro-
portional hazards. Statistical analyses were performed using statistical software SAS version
9.4 (SAS Campus Drive, Cary, NC, USA) and Stata 15.0 (Stata Corporation, College Station,
TX, USA).
Results
Demographics and phenotype of the patients in the four groups are shown in Table 1. As
expected, Group 4 patients (low S-Alb and high hsCRP) were older and had a higher preva-
lence of CVD (48%). The prevalence of diabetes mellitus was higher in Groups 2 (33%) and 4
(34%); i.e. the low S-Alb groups. Traditional cardiovascular risk factors systolic arterial blood
pressure, and total cholesterol did not differ significantly between Group 4 and Group 1. Uri-
nary albumin excretion (only available in incident dialysis and prevalent PD patients) was
higher in the two groups with lowest levels of S-Alb (Groups 2 and 4) but did not differ signifi-
cantly between the two groups. The lowest haemoglobin levels were found in Group 4 and the
higher ferritin levels in both groups with higher hsCRP (Groups 3 and 4). No significant differ-
ences in PTH and phosphate levels were observed among the groups. The inflammatory mark-
ers hsCRP, IL-6, TNF and VCAM-1 and the oxidative stress marker 8-OHdG were
significantly higher in Groups 3 and 4.
A correlation matrix is presented in Table 2. S-Alb and hsCRP correlated significantly with
most biomarkers and clinical parameters but not with residual renal function, PTH, phosphate
or cholesterol.
Anthropometric and nutritional evaluation
BMI significantly differed between the four groups with the lowest values found in Group 1.
Group 4 had significantly lower HGS than Group 1, 2 and 3 (67% vs 92%, 83% and 77%
respectively; p<0.001) and the prevalence of PEW (SGA>1) was significantly higher in Group
4 than in Groups 1, 2 and 3 (48% vs. 27%, 28% and 37%, respectively; p<0.001). When assess-
ing S-Alb in relation to nutritional status in inflamed (Groups 3–4) and non-inflamed (Groups
1–2) patients, the presence of PEW (SGA>1) was associated with presence of a low S-Alb level
only among the inflamed patients (Fig 1). In contrast, in the non-inflamed patients, presence
of a low S-Alb level did not differ between patients with PEW (SGA>1) and well-nourished
patients.
Survival analysis
Patients’ mortality (by Kaplan-Meier) (Fig 2) was significantly higher in Group 4 (p<0.001).
In contrast, no significant difference in mortality was observed for Groups 2 and 3 compared
with the reference group (Group 1). In Cox Proportional Hazard analysis adjusted for age,
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gender, CVD, diabetes mellitus, smoking, residual renal function and treatment modality,
Group 4 demonstrated higher mortality risk compared to the reference group (HR 1.62 (1.06–
2.47); p = 0.02), while Group 2 and 3 did not associate with increased mortality risk as com-
pared to Group 1 (Table 3).
These results remained in principle unchanged following several additional analyses serving
as sensitivity tests (S2 Table, S3 Table, S4 Table, S5 Table, S6 Table). Thus, association of
S-Alb with all-cause mortality risk remained when using median values for S-Alb and hsCRP;
excluding all PD patients; analyzing S-Alb as a continuous variable for low and high CRP
respectively; analyzing HR for S-Alb in the whole population without adjusting for CRP and
after adjusting for CRP; adjusting for blood pressure (instead of CVD) and adjusting for %
HGS. S-Alb remained associated with HR in the whole population without adjusting for CRP
and after adjusting for CRP. However, when adjusting for additional confounders, including
Table 2. Univariate Spearman’s Rho correlations of S-albumin and hsCRP with other parameters in
822 patients with CKD stage 5.
Characteristics d S-Albumin hsCRP
Age - 0.17c 0.30c
Gender 0.04 0.07a
Residual renal function - 0.06 - 0.02
CVD - 0.11c 0.29c
Diabetes mellitus - 0.25c 0.09b
Smoking - 0.08a 0.23c
Systolic BP - 0.10b -0.04
Diastolic BP -0.06 -0.09a
MAP - 0.09a - 0.05
Pulse Pressure - 0.12b 0.04
BMI 0.01 0.07a
SGA score >1 - 0.16c 0.23c
%Handgrip strength 0.23c - 0.32c
Hemoglobin 0.20c - 0.15c
Ferritin 0.00 0.16c
PTH - 0.01 0.00
Calcium 0.18c 0.15a
Phosphate - 0.03 0.01
Cholesterol - 0.01 - 0.04
Triglycerides 0.00 0.14c
IL-6 - 0.38c 0.64c
TNF - 0.14c 0.25c
VCAM-1 - 0.24c 0.30c
8-OHdG - 0.07 0.36c
Abbreviations: BP, blood pressure; hsCRP, high-sensitivity C-reactive protein); RRF, residual renal
function; CVD, cardiovascular disease; MAP, mean arterial pressure; BMI, body mass index; SGA,
subjective global assessment of nutritional status: PTH, parathyroid hormone; IL-6; interleukin-6; TNF,
tumor necrosis factor; VCAM-1, vascular cellular adhesion molecule-1; 8-OHdG, 8-hydroxy-
2-deoxyguanosine.
a p<0.05
b p<0.01
c p<0.001
d for number of patients for each parameter see Table 1
https://doi.org/10.1371/journal.pone.0190410.t002
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traditional CVD risk factors and uremia risk factors (age, gender, DM, BP, SGA, GFR, renal
replacement modality, %HGS, Ca x PO4, serum cholesterol, triglycerides and hemoglobin),
Group 4 (Low S-Alb and high hsCRP) was not associated with increased risk (HR 1.43 [0.94–
2.20]; p = 0.11).
Discussion
We show, for the first time, that inflammation has a catalytic effect on the genuine risk bio-
marker S-Alb. Thus, low S-Alb was found to be an independent risk predictor for poor out-
come only in the presence of inflammation whereas hypoalbuminemia without inflammation
carried a minor mortality risk. These results withstood extensive sensitivity analyses (see Sup-
plementary material). This observation accords with recent studies demonstrating that hypoal-
buminemia in the uremic milieu rather reflects persistent inflammation [6–9] than
malnutrition (i.e. PEW) and that the role of albumin as a prognostic marker [3, 30] is lost after
adjustments for inflammatory markers [31–33].
The concentration of S-Alb depends on many factors, such as the rate of hepatic synthesis
and secretion, exchanges between intra- and extravascular compartments, lymphatic uptake,
alterations of the volume of distribution and protein degradation rate, and body losses [6, 24].
During systemic inflammation, opposing the reduced albumin degradation that accompanies
low intake or body losses, the catabolism of albumin is increased, leading to declining S-Alb
concentrations [34]. Due to its long half-life, a single measurement of S-Alb is likely to reflect a
more prolonged period or a more relevant state of uremic inflammation than the “moving tar-
gets” of CRP and IL-6 in the highly variable uremic milieu [16, 22]. In fact, we show that the
two groups of inflamed subjects present different levels of inflammation and the group with
higher levels of inflammatory markers is the one with low albumin. Hypoalbuminemia can
also reflect malnutrition severe enough to disturb the albumin synthesis capacity needed to
maintain albumin homeostasis. Because of the abovementioned central role of S-Alb in body
homeostasis, many factors linked to clinical outcome are causually associated with the
Fig 1. Association between S- albumin and subjective global assessment score (SGA) in 822 CKD
stage 5 patients, according to inflammatory status. Inflamed and non-inflamed were defined according to
hsCRP concentrations above or below 3 mg/L.
https://doi.org/10.1371/journal.pone.0190410.g001
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Fig 2. Kaplan-Meier survival curves during 60 months follow-up in 822 CKD stage 5 patients divided into four groups according to levels of
hsCRP (high3mg/L, or normal <3mg/L) and S-Alb (low <35 g/L, or normal35g/L). Group 1 (n = 200): Normal S-Alb and normal hsCRP; Group 2
(n = 160): Low S-Alb and normal hsCRP; Group 3 (n = 172): Normal S-Alb and high hsCRP; Group 4 (n = 290) Low S-Alb and high hsCRP.
https://doi.org/10.1371/journal.pone.0190410.g002
Table 3. All-cause mortality risk associated with low S-Alb <35 g/L and high hsCRP3 mg/L (Group 4) during 60 months of follow-up.
Crude HR (95% CI) p value Adjusted imputed
HR (95% CI)
p value
Group 2
Low albumin
Normal hsCRP
1.63 (0.98–2.73) 0.05 1.04 (0.61–1.76) 0.89
Group 3
Normal albumin
High hsCRP
2.30 (1.46–3.62) <0.001 1.27 (0.80–2.03) 0.29
Group 4
Low albumin
High hsCRP
3.35 (2.22–5.04) <0.001 1.62 (1.06–2.47) 0.02
Data are presented as hazard ratios (HR) with 95% confidence interval (CI) crude and adjusted for confounding factors (age, gender, CVD, DM, smoking,
SGA, GFR and renal replacement technique), using Group 1 as reference. Imputed smoking status was used in 144 patients.
https://doi.org/10.1371/journal.pone.0190410.t003
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concentration of S-Alb, and residual confounding is therefore likely a potential limitation in
the current as well as previous studies.
Even though all inflammatory markers were higher in Group 4, appropriate cut-offs of
these markers for risk assessment have not been established and they are therefore not useful
to stratify the degree of severity of inflammation in CKD. The increased risk in Group 3,
despite being non-significant, supports that inflammation carries risk, but there is no consen-
sus for stratification according to inflammation level. We also used median values of hsCRP
(and S-Alb) in the statistical analyses, and the results remained essentially the same. Cut-offs
derived from ROC curve analysis of biomarker concentrations in relation to all-cause mortal-
ity may yield meaningful cut-offs. However, the shape of the ROC curve for S-Alb was rela-
tively flat (S1 Fig). Thus, the definition of an optimal cut-off value for S-Alb is uncertain.
Repeated measurements of inflammatory markers, such as hsCRP, have shown to be better
predictors of mortality [16] but this approach is seldom possible in clinical practice. Therefore,
the combination with an established risk biomarker with a stable temporal profile, such as
S-Alb, is of value in the clinical situation.
The high prevalence of CVD and PEW in the two inflamed patient groups supports the
documented strong association between inflammation, atherosclerosis and malnutrition
(MIA) [19, 35–37]. It is notable that despite the high overall prevalence of CVD in these
patients, the traditional cardiovascular risk factors were not consistently augmented. This
observation accords with the reported lack of validity of Framingham risk assessment for risk
stratification in CKD [38] and the need for developing new risk scores validated for these
patients [39].
It is notable that the nutritional status (according to SGA and HGS) in the group of patients
with low S-Alb in an uninflamed milieu (Group 2) did not differ from the patients with normal
S-Alb levels and uninflamed milieu (Group 1). The lower BMI in the group with normal S-Alb
and low hsCRP, the group with better survival, are not congruent with the reported paradox of
obesity being a survival factor in ESRD patients [40]. However, only 11.1% of the 822 patients
were considered obese according to BMI, a lower prevalence than in most other populations
[41]. Moreover, it has been demonstrated that inflammation modifies also the association
between BMI and mortality [42]. A major finding of the present study is that PEW (by SGA)
modifies the relationship between S-Alb/hsCRP grouping and outcome. Importantly, we
observe that low S-Alb in an uninflamed milieu (Group 2) or normal S-Alb in an inflamed
milieu (Group 3) predicts increased risk only in CKD5 patients with signs of PEW. Thus, like
inflammation, the presence of PEW changes the risk factor profile.
Oxidative stress is a common feature of the inflamed uremic milieu that acts as a unifying
mechanism for many cardiovascular risk factors and cardiovascular mortality [43, 44]. It pro-
motes accelerated vascular aging via endothelial dysfunction [37], increased oxidative modifi-
cations of proteins [45] and vascular calcification [46]. Indeed, in Group 4 we report higher
levels of the oxidative stress marker 8-OHdG, a major product of DNA oxidative damage that
predicts increased mortality in dialysis patients [27]. Together with the increased exposure to
inflammatory stimulus, CKD patients are subjected to increased susceptibility to oxidative
stress caused in part by lower levels of antioxidants [43, 44]. It should be noted that S-Alb itself
is a major antioxidant [13, 47], and a free-radical scavenger due to its thiol groups that act by
preventing oxidative injury to both lipoproteins and the vascular wall [48]. This accords with
Kim et al. [49] who showed that endothelial function markers were correlated with S-Alb.
Since CRP did not normalize with albumin infusion, this suggests that the relationship
between low S-Alb levels and endothelial dysfunction is intermediated by inflammation. Thus,
oxidative stress (as a consequence of inflammation) combined with hypoalbuminemia [43]
will lead to a vicious cycle of more deleterious consequences including deterioration of the
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nutritional status [50, 51]. Inflammatory cytokines promote PEW by acting directly on the gas-
trointestinal system or indirectly through affecting appetite and resting energy expenditure [7,
52]. Moreover, low S-Alb and congestive heart failure may promote intestinal edema [53] and
disturb the absorption of essential nutrients and anti-oxidative vitamins and oligoelements
[54]. These multiple interactions [55] contribute to the higher cardiovascular burden and mor-
tality in CKD5 patients with persistent inflammation and lower albumin (Fig 3).
Some strengths and limitations should be considered when the results of the present study
are interpreted. The study benefits from the careful phenotyping and inclusion of several tradi-
tional and non-traditional risk factors in a relatively large population of CKD5 patients. To the
best of our knowledge, this is the first study in which the risk factor modifying effect of CRP
on the well-established risk biomarker S-Alb is observed. The absence of patients lost to fol-
low-up also strengthens our study. Limitations to be acknowledged are, at first, the age of
patients in the four different groups is statistically different which might explain some of the
differences found in anthropometric parameters. The absence of residual renal function in
prevalent HD patients also limits the interpretation of its contribution to the outcomes. Our
study comprised both incident and prevalent dialysis patients with somewhat different inclu-
sion criteria. However, in the multivariate analysis, patient cohorts were taken into account,
and all anthropometric and laboratory analyses were made with the same methods and tech-
niques. Nevertheless, a number of factors influence the levels of both S-Alb and hsCRP and
residual confounding remains as a potential limitation. We also acknowledge that since mor-
tality tended to be higher in Group 3 (Fig 2) we cannot exclude a type-2 statistical error due to
lack of power. Thus power is likely playing a role in the lack of significance in Group 3. Since
inflammation markers are “moving targets”, the lack of repeated sampling of inflammatory
markers limits the interpretation of the study. We recently showed that short-term variability
of IL-6 and CRP strongly associated with PEW [56]. We also did not measure oxidized albu-
min levels, which could have had an impact on our results, as it is shown to be related with
augmented oxidative stress and metabolic syndrome [57]. The quantification of albumin in
peritoneal dialysis dialysate was not performed, which could be an important confounder to
Fig 3. Inflammation/oxidative stress, resulting in hypoalbuminemia, interacts with cardiovascular
disease (CVD) and protein-energy wasting (PEW) and together these changes contribute to the
increased mortality in end-stage kidney disease.
https://doi.org/10.1371/journal.pone.0190410.g003
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the albumin levels in this group of patients; however, results were essentially unchanged when
we excluded PD patients. Finally, we stratified patients according to S-Alb and CRP cut-offs
currently used in clinical practice; however, the best cut-off levels for risk prediction in end
stage CKD patients remain to be determined. For this purpose, future studies comprising
larger cohorts of patients are warranted and should take into account that the relationship
between CRP and albumin concentration is non-linear.
In conclusion, a low S-Alb concentration was an independent risk factor for poor outcome
in CKD stage 5 only in the presence of systemic inflammation. Based on this observation we
suggest that when using S-Alb to predict mortality risk in CKD stage 5 patients, CRP should
always be assessed and considered.
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